Ajaz Hussain and Wuxi Apptec’s Dr Minzhang Chen join 12 strong CPHI Annual Industry report experts

2016 report topics include 3D printing, FDA quality metrics, contract services, pharma growth in China and India, and generic licensing.

This year, the CPHI Annual Report will see 10 experts returning from 2015, along with two new valuable additions: Ajaz Hussain, Founder and CEO at Insight Advice & Solutions LLC (also the current president of NIPTE) and Dr Minzhang Chen, CEO of STA Pharmaceuticals – the API development and manufacturing division of Wuxi Apptec.

Dr Minzhang Chen is known globally in the pharmaceutical and biopharmaceutical industry and has more than 18 years of experience in Process R&D and API Manufacturing. STA pharmaceutical is the leading China based CDMO and is a standard bearer of emerging research in China and globally.

Ajaz Hussain is a widely recognized leader within pharmaceuticals and drug development, having previously worked at the FDA, Wockhardt and Sandoz. He is an internationally renowned thought leader on pharmaceutical manufacturing, research and harmonisation – he served as the FDAs ICH lead, expediting the progress and implementation of ICH Q8, Q9 and Q10.

The 2016 report will provide an overview of contract services growth, predictions on continuous processing and 3D printing of finished formulations. Brian Carlin of FMC will look at the role of excipients, whereas Prabir Basu will explore new types of FDA quality metrics. Generics are also a central part of two expert contributions – from Alan Sheppard and Dilip Shah – who will analyse overall growth and licensing trends. In addition, Bikash Chatterjee will explain the how the management of data and information in pharma will be key to defining the industry in the next decade.

The Chinese and Indian global pharma economies continue to drive growth, and representatives from Piramal, Biocon and Wuxi Apptec will examine factors affecting the markets in the next 2-5 years.

“This year’s annual report features over 200+years of high level pharma expertise providing unparalleled insights into global trends, issues and challenges over the short and medium term. The panel provides a balanced view of experts from independent consultants and representatives from all the major pharma economies.

"As the pharma industry continues to globalise and new technologies emerge, access to information on how to implement new methods and development will become increasingly business critical to both pharma and supply side companies. Our annual report is released to help the industry stay informed, to stimulate debate and collaborations, and more quickly develop the pharmaceutical products of tomorrow,” commented Chris Kilbee, Group Director Pharma at UBM EMEA.